Drug Trial Radar · NCT05088460
A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD)
Last checked: Nov 20, 2026Latest source record: Oct 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
20
Actual
Start
Feb 28, 2022
Primary completion
Dec 13, 2023
Study completion Apr 18, 2024
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Oct 22, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Two cohorts are being studied based on leptin levels. Cohort A is composed of patients with baseline leptin \<8.0 ng/mL and Cohort B is composed of patients with baseline leptin 8.0 to ≤20.0 ng/mL The primary objectives will be evaluated for patients in Cohort A only: * To evaluate the effect of REGN4461 on fasting triglycerides (TG) in patients with elevated baseline fasting TG * To evaluate the effect of REGN4461 on hyperglycemia in patients with elevated baseline Hemoglobin A1c (HbA1c) The following secondary objectives of the study will be evaluated for Cohort B and for the combined set of Cohorts A plus B: * To evaluate the effect of REGN4461 on fasting TG levels in patients with hypertriglyceridemia * To evaluate the effect of REGN4461 on glycemic control in patients with hyperglycemia The following secondary objectives of the study will be evaluated for Cohorts A and B separately, and for the combined set of Cohorts A plus B: * To evaluate the effect of REGN4461 on liver fat in patients with hepatic steatosis * To evaluate the effect of REGN4461 on hunger * To evaluate safety and tolerability of REGN4461 * To characterize the concentration profile of REGN4461 over time * To assess immunogenicity to REGN4461
Conditions
- Familial Partial Lipodystrophy
- Metabolic Abnormalities
Interventions
REGN4461Drug
Intravenous (IV) infusion loading dose followed by subcutaneous (SC) injection weekly (QW).
Matching PlaceboDrug
Intravenous (IV) infusion loading dose followed by subcutaneous (SC) injection weekly (QW).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline to Week 12 in Fasting Serum Triglyceride (TG) (Cohort A)Time frame: Baseline to week 12
- Change From Baseline to Week 12 in Hemoglobin A1c (HbA1c) (Cohort A)Time frame: Baseline to week 12
Locations
8 sites in 4 countries. Site status is shown where the registry gives one.
Excel Medical Clinical Trials - A Flourish Research Site
Boca Raton, Florida
National Institute of Health
Bethesda, Maryland
University of Michigan
Ann Arbor, Michigan
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
UT Southwestern Medical Center
Dallas, Texas
ICAN, Institute of Cardiometabolism and Nutrition
Paris, France
Complexo Hospitalario Universitario de Santiago-Hospital Médico-Cirúrxico de Conxo
Santiago de Compostela, Galicia, Spain
Ege University Faculty of Medicine
Izmir, Bornova, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.